Cancer cellSmart mesoporous silica nanoparticle

Silica based smart solutions for targeted therapy

Blood vesselTumor

Luigi Pasqua-CEOwww.nanosilicaldevices.com/en

What problems we solve?

Costumers’ problems• Drug patent expiration• Antineoplastic drugs toxicity

Already existing drugs New drugs

Patient non-adherence to treatment causes a

loss of 36% of potential sales per

drug

Patients’ problems

• side effects• hospitalization

We are developing Mesoporous Silica-based Nanodevices (MSN) bearing:• a targeting molecule on the outer surface and• an antineoplastic drug linked within the pores by means of a pH-sensitive

bond.MSNs ca be exploited as vehicles for targeting and release of biologically activemolecules, to be employed in targeted therapy.

Our technology

Ordered porous structure with pore diameter between 2nm and 50nm

1, Cellular recognition

3, Intracellular drug release

2, System internalization

Our solution: features

Mesoporous Silica Nanoparticles (MSNs) for targeted therapy

Main Features Targeting function pH sensitive drug release

• easily synthesized• versatile• biocompatible • soluble in biological fluids

prolong the life cycle of already established drugs, through a new IP

improve tolerability of new drugs

….for customers

….for patients

lower drug dosage higher efficacy improved adherence to therapy reduced side effects

Our solution: advantages

Competitive Advantages

COMPANY High

Versatility Applications in Drug Delivery

Excellent Physical and

Chemical Stability

Biocompatible and

Biodegradable

High Suspendibility in water and in organic fluids

Target

Specificity

Ph-dependent drug release

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

V

The Market

MultipleMyeloma

$9B by 2021

MSN-BTZ(1st product)

Global Antitumoral

Drugs$112B by 2020

MSN-X(2nd product)

MSN-Y(3rd product)

MSN-Z(n product)

Our team

Luigi Pasqua CEO, lead inventor of MSN technology and co-founder

Researcher in Material Science and Technology, Dep. of

Engineering, University of Calabria

Antonella LeggioCRO and co-founder

Professor of Organic Chemistry, Dep. of Pharmacy, University of

Calabria

Massimo Iacobelli, MD Consultant for biotech/pharma

companies. Past VP Scientific and Medical Director of Gentium SpA

.

Paul Richardson, MDDirector of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Professor of Medicine, Harvard Medical School,

Boston, MA, USA

Jawed Fareed, PhDProfessor of Molecular Pharmacology and Therapeutics, Loyola University,

Chicago, IL, USA

MANAGEMENTADVISORS

Catia Morelli CRO and co-founder

Research Associate in General Pathology Dep. of Pharmacy,

University of Calabria

Milestones

2004-2013 -> The idea (academic research)

2014 -> NanoSiliCal Devices foundation( €250.000,00 co-financing fromRegion Calabria for Spin-Off creation)

September 2016 -> Grant Horizon 2020 SME instrument, Phase1

April 2016-> PCT/IT2016/000111

August 2016 -> EP2001514

€75K - Region Calabria (public grant for

SME Innovation)

Joint Ventures with Qatarian investors for an initial investment of 125.000 euros.

PARTNERS CUSTOMERS

Aprile 2017-> start joint-venture between

NanoSiliCal Devicesand Mr. M.A. Al Emadi

Doha, Qatar

The Sidra Medical and Research Center

The Qatar Science and Technology Park

The joint venture with Mr. Al-Emadi from Qatar

Year III

1st PRODUCT

Business model

Year I (2017)

2nd PRODUCT

Year II

Customercontact 2-3 new

prototypes(engineering)

Customercontact

EMA ADVICES

Luigi Pasquainfo@nanosilicaldevices.com

www.nanosilicaldevices.com/en

TODAY

Clara

has cancer and she is receiving

NSD targeted chemotherapy

OUR VISION

Marygot cancer and she is receiving

classical chemotherapy

NanoSiliCal Devices:Silica based smart solutions for targeted therapy